CANDISS TRAGER: Open Payments
NPI 1881117679 · KYLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,072 in 129 payments from 16 companies in 2025. Trend: 2023 $1,633 · 2024 $2,474 · 2025 $3,072
Food & beverage: $2,442Consulting: $630
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 17 | $1,051 |
| GlaxoSmithKline, LLC. | 48 | $498 |
| AstraZeneca Pharmaceuticals LP | 14 | $428 |
| Regeneron Healthcare Solutions, Inc. | 12 | $350 |
| United Therapeutics Corporation | 13 | $229 |
| Verona Pharma, Inc. | 6 | $145 |
| Electromed, Inc. | 4 | $76 |
| Grifols USA, LLC | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
Products named: DUPIXENT, NUCALA, FASENRA, TRELEGY ELLIPTA, Tyvaso, Ohtuvayre, AIRSUPRA, SMARTVEST.
Industry payments across TX — which companies pay providers there.
